Regeneron 3Q Revenues: $1.2 billion (7%) 3Q Earnings: $265.0 million (+26%) YTD Revenues: $3.6 billion (+21%) YTD Earnings: $642.4 million (+34%) Comments: Product sales were $857 million in the quarter, up 16%. Sales of EYLEA in the U.S. increased 16% to $854 million in the quarter. Sales of Praluent were $38 million, compared to $4 million in 3Q15 when the product was launched in the U.S. Product sales for Praluent are recorded by Sanofi, and the company shares in any profits or...